NYSE:DVAHealthcare
DaVita Confronts Volume Pressure While Expanding Integrated Kidney Care Model
DaVita (NYSE:DVA) is contending with declining patient volumes that are weighing on its core dialysis operations.
The company is responding by putting more resources into clinical programs and integrated kidney care offerings.
These initiatives are intended to reshape how DaVita serves patients over the coming years, with implications for its business mix and cost profile.
DaVita, trading around $149.94, sits at an important inflection point as it works through this pressure on its dialysis...